Journal of Internal Medicine Concepts & Practice ›› 2021, Vol. 16 ›› Issue (01): 49-52.doi: 10.16138/j.1673-6087.2021.01.011
• Research report • Previous Articles Next Articles
Received:
2020-08-28
Online:
2021-02-25
Published:
2022-07-26
CLC Number:
指 标 | 无钙化组(n=47) | 钙化组(n=27) | t/χ2 | P |
---|---|---|---|---|
年龄(岁) | 48.26±13.52 | 53.07±12.95 | -1.499 | 0.138 |
男性 | 23(48.9) | 18(66.7) | 2.182 | 0.140 |
ESRD原因[n(%)] | 1.809 | 0.405 | ||
肾小球肾炎 | 44(93.6) | 24(88.9) | ||
糖尿病 | 2(4.3) | 3(11.1) | ||
高血压 | 0(0.0) | 0(0.0) | ||
其他 | 1(2.1) | 0(0.0) | ||
糖尿病史[n(%)] | 2(4.3) | 3(11.1) | 1.279 | 0.258 |
吸烟史[n(%)] | 7(14.9) | 10(37.0) | 4.752 | 0.029 |
收缩压(mmHg) | 124.89±17.79 | 133.59±14.62 | -2.155 | 0.034 |
舒张压(mmHg) | 81.57±12.42 | 85.44±8.43 | -1.591 | 0.116 |
平均动脉压(mmHg) | 95.57±12.85 | 101.49±9.48 | -2.085 | 0.041 |
BMI(kg/m2) | 21.39±3.22 | 24.80±3.39 | -4.299 | 0.000 |
总Kt/V | 1.77 (1.61,1.95) | 1.69 (1.53,1.80) | -0.593 | 0.553 |
总 CCR/(L/周) | 54.60(46.93,63.58) | 49.01(43.08,56.81) | -1.233 | 0.218 |
残余肾Kt/V | 0.27 (0.00,0.58) | 0.02 (0.00,0.29) | -1.038 | 0.299 |
残余肾 CCR/(L/周) | 14.01 (0.00,30.56) | 1.45 (0.00,15.48) | -0.858 | 0.391 |
D/P | 0.63±0.10 | 0.62±0.07 | 0.293 | 0.770 |
CAPD[n(%)] | 42(89.4) | 25(92.6) | 0.209 | 0.648 |
使用低钙透析液[n(%)] | 46(97.9) | 26(96.3) | 0.162 | 0.687 |
腹透时间(月) | 60.00 | 33.00 (24.00,48.00) | ||
使用降磷药物[n(%)] | 40(85.1) | 22(81.5) | 0.166 | 0.684 |
使用骨化三醇[n(%)] | 36(76.6) | 15(55.6) | 3.544 | 0.060 |
使用调脂药物[n(%)] | 26(55.3) | 12(44.4) | 0.812 | 0.368 |
FA浓度(mg/L) | 351.68±62.36 | 310.68±62.58 | 2.719 | 0.008 |
血红蛋白(g/L) | 110.70±15.76 | 112.56±12.02 | -0.529 | 0.599 |
血清铁(μmol/L) | 13.00 (10.50,18.40) | 10.60 (7.50,15.10) | -1.892 | 0.058 |
运铁蛋白(g/L) | 1.83 (1.57,2.14) | 1.81 (1.61,2.17) | -0.061 | 0.952 |
铁蛋白(mg/L) | 204.90 (113.00,340.70) | 148.80 (101.60,296.50) | -0.326 | 0.745 |
TS (%) | 30.00 (24.00,43.00) | 26.00 (19.00,33.00) | -1.827 | 0.068 |
AKP(U/L) | 78.00 (65.00,120.00) | 72.00 (59.00,98.00) | -1.185 | 0.236 |
校正钙mmol/L) | 2.34 (2.17,2.44) | 2.43 (2.32,2.51) | -1.829 | 0.067 |
磷(mmol/L) | 1.58±0.49 | 1.69±0.40 | -0.965 | 0.338 |
钙磷乘积(mmol/L)2 | 3.56 (2.75,4.22) | 3.86 (3.26,4.63) | -1.440 | 0.150 |
iPTH(ng/L) | 289.0 (225.0,426.0) | 242.0 (198.0,280.0) | -1.881 | 0.060 |
超敏CRP | 0.42 (0.21,2.21) | 3.52 (0.46,5.46) | -2.424 | 0.015 |
白蛋白(g/L) | 37.85±4.88 | 37.15±3.81 | 0.644 | 0.522 |
前白蛋白(g/L) | 381.00 (335.00,434.00) | 370.00 (318.25,425.25) | -1.018 | 0.309 |
糖化血红蛋白(%) | 5.20 (4.90,5.70) | 5.50 (5.20,5.90) | -2.302 | 0.021 |
血清胰岛素(pmol/L) | 9.90 (5.90,13.30) | 12.80 (9.80,16.70) | -2.184 | 0.029 |
HOMA-IR | 2.20 (1.44,3.01) | 3.00 (2.04,4.12) | -2.032 | 0.042 |
三酰甘油(mmol/L) | 1.57 (1.10,2.45) | 2.36 (1.17,3.13) | -1.611 | 0.107 |
总胆固醇(mmol/L) | 4.22±0.94 | 3.92±0.79 | 1.406 | 0.164 |
HDL-C(mmol/L) | 0.95 (0.76,1.22) | 0.76 (0.62,0.88) | -3.381 | 0.001 |
LDL-C(mmol/L) | 2.15 (1.64,2.46) | 1.86 (1.28,2.20) | -2.173 | 0.030 |
变量 | β | Sig | OR | 95% CI |
---|---|---|---|---|
FA | -0.580 | 0.015 | 0.560 | 0.351~0.892 |
吸烟史 | 1.212 | 0.034 | 3.361 | 1.096~10.304 |
校正钙 | 0.453 | 0.046 | 1.573 | 1.008~2.454 |
iPTH | -0.471 | 0.042 | 0.625 | 0.397~0.983 |
糖化血红蛋白 | 0.535 | 0.022 | 1.707 | 1.079~2.700 |
胰岛素 | 0.525 | 0.025 | 1.690 | 1.068~2.675 |
HOMA-IR | 0.471 | 0.042 | 1.601 | 1.017~2.519 |
LDL-C | -0.506 | 0.030 | 0.603 | -0.381~-0.953 |
HDL-C | -0.719 | 0.003 | 0.487 | 0.301~0.789 |
超敏CRP | 0.543 | 0.030 | 1.722 | 1.054~2.812 |
BMI | 1.464 | 0.002 | 4.324 | 1.6921~1.053 |
平均动脉压 | 0.471 | 0.041 | 1.601 | 1.019~2.516 |
[1] |
Rogan A, McCarthy K, McGregor G, et al. Quality of life measures predict cardiovascular health and physical performance in chronic renal failure patients[J]. PLoS One, 2017, 12(9): e0183926.
doi: 10.1371/journal.pone.0183926 URL |
[2] |
Fukao W, Hasuike Y, Yamakawa T, et al. Oral versus intravenous iron supplementation for the treatment of iron deficiency anemia in patients on maintenance hemodialysis-effect on fibroblast growth factor-23 metabolism[J]. J Ren Nutr, 2018, 28(4): 270-277.
doi: 10.1053/j.jrn.2017.12.009 URL |
[3] |
Wang AY. Calcium balance and negative impact of calcium load in peritoneal dialysis patients[J]. Perit Dial Int, 2014, 34(4): 345-352.
doi: 10.3747/pdi.2013.00177 URL |
[4] | 晏焕青, 谢琼虹, 尚达, 等. 冠脉钙化积分与腹膜透析患者预后的相关性研究[J]. 上海交通大学学报(医学版), 2017, 37(8): 1120-1126. |
[5] |
Taylor AJ, Burke AP, O'Malley PG, et al. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death[J]. Circulation, 2000, 101(11): 1243-1248.
pmid: 10725282 |
[6] |
Dabrowska AM, Tarach JS, Wojtysiak-Duma B, et al. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159(3): 352-359.
doi: 10.5507/bp.2015.018 URL |
[7] |
Chen HY, Chiu YL, Hsu SP, et al. Relationship between fetuin A, vascular calcification and fracture risk in dialysis patients[J]. PLoS One, 2016, 11(7): e0158789.
doi: 10.1371/journal.pone.0158789 URL |
[8] |
Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography[J]. J Am Coll Cardiol, 1990, 15(4): 827-832.
doi: 10.1016/0735-1097(90)90282-t pmid: 2407762 |
[9] |
Lu W, Ren C, Han X, et al. The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis[J]. Medicine (Baltimore), 2018, 97(37): e12325.
doi: 10.1097/MD.0000000000012325 URL |
[10] | Cai MM, Wigg B, Smith ER, et al. Relative abundance of fetuin- A in peritoneal dialysis effluent and its association with in situ formation of calciprotein particles: an observational pilot study[J]. Nephrology (Carlton), 2015, 20(1): 6-10. |
[11] | 莫颖, 任荣, 张艳, 等. 血清胎球蛋白A、C反应蛋白及骨保护素水平与血液透析患者血管钙化相关性研究[J]. 临床肾脏病杂志, 2019, 19(11): 853-856. |
[12] | 张曼, 张京慧, 温小军, 等. 老年血液透析患者血清hs-CRP、Fetuin-A水平与心脏瓣膜钙化和血管钙化的关系[J]. 分子诊断与治疗杂志, 2020, 12(3): 296-299. |
[13] |
Rroji M, Figurek A, Spasovski G. Should we consider the cardiovascular system while evaluating CKD-MBD[J]?. Toxins (Basel), 2020, 12(3): 140.
doi: 10.3390/toxins12030140 URL |
[14] | 尹飞挺, 周婷婷, 周岩, 等. 腹膜透析患者心血管钙化的发生率及影响因素[J]. 肾脏病与透析肾移植杂志, 2015, 24(5): 435-440. |
[15] | 买合丽亚·卡买尔江, 黄莺. 探讨冠脉钙化积分和冠脉钙化危险因素与新疆不同民族人群冠脉钙化的相关性研究[J]. 中西医结合心血管病电子杂志, 2019, 7(21): 67-69. |
[16] |
Ouwens DM, Sell H, Greulich S, et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease[J]. J Cell Mol Med, 2010, 14(9): 2223-2234.
doi: 10.1111/j.1582-4934.2010.01141.x URL |
[1] | ZHANG Xiaoyan, XU Jing, QU Bin. Effect of serum vitamin D level on renal function in elderly patients with chronic kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 307-312. |
[2] | ZHANG Chunli, XU Jing, PAN Xiaoxia, HU Xiaofan, LI Ya. Analysis of clinical and histological features of IgG4-related kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 214-219. |
[3] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(05): 366-370. |
[4] | XUAN Yingli, CHEN Feihong, QIN Li, HE Ruibin, PANG Shiqing, YUAN Jiangzi. Correlation analysis of vitamin D and nocturnal blood pressure in the patients with chronic kidney disease [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 246-250. |
[5] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 4-9. |
[6] | WANG Xuejie, CHEN Zijin, DU Wen, GU Feifei, YU Haijin, ZHANG Wen, CHEN Xiaonong. Risk factors of acute kidney injury in the patients with bloodstream infection caused by different pathogens [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 22-26. |
[7] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 15-17. |
[8] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 10-14. |
[9] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 1-3. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||